Skip to main content
M

MegaPro Biomedical Co. Ltd. — Investor Relations & Filings

ISIN · TW0006827009 TPEX Professional, scientific and technical activities
Open in API
Filings indexed 1 across all filing types
Latest filing 2025-06-30 Legal Proceedings Report
Country MY Malaysia
Listing TPEX

About MegaPro Biomedical Co. Ltd.

https://www.megaprobio.com/en/

MegaPro Biomedical Co., Ltd. is a clinical-stage biotechnology company specializing in the development of nano drugs and advanced nanomedicine platforms. The company utilizes its proprietary nano-cell technology, centered on nano iron oxide particles, to create novel therapeutics and diagnostic agents. Its diversified pipeline targets oncology, diagnostic imaging, and hematology. Key programs in clinical development include MPB-1734, a new formulation anti-cancer drug; MPB-2043, a magnetic resonance imaging (MRI) contrast agent for cancer staging; and MPB-1514, an iron injection for the treatment of iron deficiency anemia. The company actively advances its portfolio through integrated research and development and the execution of clinical trials for its nanomedicine candidates.

Recent filings

Filing Released Lang Actions
MegaPro s MPB-1734 Expected to Seek Prostate Cancer NDA via 505(b)(2) Pathway Supported by Bioequivalence Study
Legal Proceedings Report Classification · 1% confidence The document is a press release dated June 30, 2025, announcing a corporate update regarding MegaPro Biomedical Co., Ltd.'s drug candidate MPB-1734. It details the outcome of a Type C meeting with the U.S. FDA concerning the regulatory pathway (505(b)(2) NDA via bioequivalence study) for a prostate cancer treatment. This type of announcement, focusing on regulatory feedback, clinical progress, and market potential, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material business update that is not a full financial report (10-K, IR) or a transcript (CT), and it is not explicitly announcing the publication of a separate report (RPA), it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a quarterly period. Given the nature of the announcement (FDA feedback, market size, technology platform validation), it is a significant corporate event announcement. As it doesn't fit the specific definitions of ER (which usually contains key financial figures) or other categories, RNS (Regulatory Filings / miscellaneous announcements) is the most appropriate fallback, although it shares characteristics with an ER. However, since it is a specific regulatory/development update, RNS is chosen as the general regulatory announcement category.
2025-06-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.